Long-term results of coronary artery bypass grafting in patients with ischemic cardiomyopathy: the impact of renal insufficiency and noncardiac vascular disease

J Card Fail. 2005 Apr;11(3):206-12. doi: 10.1016/j.cardfail.2004.07.008.

Abstract

Background: We examined outcomes of patients with ischemic cardiomyopathy (ICMP), defined by left ventricular ejection fraction (LVEF) <35%, compared with patients with better-preserved LVEF, undergoing coronary bypass graft surgery (CABG). In addition, we examined the relative impact of a reduced LVEF in comparison with other comorbidities on long-term mortality in these patients.

Methods and results: We evaluated 1381 patients (114 with ICMP, 1267 with better-preserved LVEF) who underwent isolated CABG at a tertiary Veterans Administration (VA) hospital between 1990 and 2000 using data from the VA Continuous Improvement in Cardiac Surgery Program and other VA databases. The 5-year survival was 74.0% in patients with ICMP and 84.4% in the group with better-preserved LVEF ( p = .005). LVEF <35% remained a significant predictor of long-term mortality in multivariable models (hazard ratio [HR] 1.55, 95% confidence interval [CI] 1.02-2.35). However, the presence of comorbidities, especially renal insufficiency, peripheral vascular disease, and cerebrovascular disease, had a similar or greater impact on long-term mortality. Renal insufficiency (serum creatinine >1.5 mg/dL) was associated with the highest risk of long-term mortality (HR 2.02, 95% CI 1.46-2.80). The use of a left internal thoracic artery graft reduced the risk of long-term mortality (HR 0.72, 95% CI 0.54-0.98).

Conclusion: Even though severely depressed LVEF is associated with an increased risk of long-term mortality, the presence of comorbid factors, especially renal dysfunction and noncardiac vascular disease, increase the risk of long-term mortality by a similar or even larger magnitude. These comorbid factors should be given important consideration when evaluating the risks and benefits of CABG.

Publication types

  • Comparative Study
  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Age Factors
  • Cardiomyopathies / mortality*
  • Cardiomyopathies / therapy
  • Cerebrovascular Disorders / mortality
  • Cohort Studies
  • Coronary Artery Bypass*
  • Diuretics / therapeutic use
  • Female
  • Hospitals, Veterans
  • Humans
  • Male
  • Mammary Arteries / transplantation
  • Middle Aged
  • Myocardial Ischemia / mortality*
  • Myocardial Ischemia / therapy
  • Peripheral Vascular Diseases / mortality
  • Pulmonary Disease, Chronic Obstructive / mortality
  • Renal Insufficiency / mortality
  • Retrospective Studies
  • Stroke Volume / physiology
  • Survival Analysis
  • Texas / epidemiology
  • Ventricular Dysfunction, Left / mortality*
  • Ventricular Dysfunction, Left / physiopathology
  • Ventricular Dysfunction, Left / therapy

Substances

  • Diuretics